Oragenics (OGEN) Receivables - Other (2016 - 2023)

Oragenics' (OGEN) quarterly Receivables - Other came in at $21941.0 in Q3 2023, up 414.03% on a QoQ basis from -$6987.0 in Q1 2022.

Oragenics (OGEN) Receivables - Other (2016 - 2023) Analysis & Trends

Oragenics (OGEN) has 4 years of Receivables - Other data on file, last reported at $21941.0 in Q3 2023.

Quarterly Receivables - Other changed N/A year-over-year to $21941.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $21941.0 (changed N/A YoY) and the FY2025 annual result came in at $53082.0, changed N/A from the prior year.
Receivables - Other rose to $21941.0 in Q3 2023, from -$6987.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $21941.0 in Q3 2023 to a low of -$6987.0 in Q1 2022.
A 3-year average of $7313.7 and a median of $6987.0 in 2021 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Oragenics	2.38 Mn	2.38 Mn	-

Download Data